Needham & Company analyst Stephen Unger lowered the price target on Genomic Health Inc. (NASDAQ: GHDX) to $69.00 (from $97.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE